In collaboration with:
Organised by:
Larry Hirsch is Vice President, Global Medical Affairs for BD Diabetes Care since 2006. Dr. Hirsch provides medical perspective to the business, engages widely with KOLs and professional societies, designs and reports DC clinical trials, worldwide. He initiated DC’s published studies on skin and subcutaneous fat thickness at injection sites, the performance of the world’s first 4mm x 32G insulin pen needle, and the impact of other needle design innovations on intramuscular injection risk, pain, ease of use, and patient preference. Larry has co-authored several studies on lipohypertrophy diagnosis, prevalence, and impact on insulin absorption and action, as well as the New Recommendations for insulin injection, from the FITTER Workshop. He also provides medical direction to development programs in DC for novel devices and technologies for diabetes.
Dr. Hirsch previously spent nearly 18 years at Merck, where he oversaw clinical outcome studies with statins, and led the global development of alendronate (Fosamax®), the first non-hormonal treatment for osteoporosis approved by the FDA.
Dr. Hirsch graduated from Harvard Medical School, and is board-certified in Internal Medicine and in Endocrinology & Metabolism. He has lived a very active life with type 1 diabetes, taking insulin > 59 years – Larry is a recipient of the Joslin Clinic’s 50-year Medal.
